Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 6:13 AM EDT
Terminated Phase 2 Interventional Results available

Fluoxetine for Visual Recovery After Ischemic Stroke

NCT02737930
View directory record Official record
Conditions
Acute Stroke, Visual Field Loss
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Bogachan Sahin
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Sedatives on Tobacco Use Disorder Version 2

NCT05505630
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Ketamine, Midazolam, Dexmedetomidine, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 1 Interventional

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

NCT06063330
View directory record Official record
Conditions
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions
RQ-001, Placebo
Combination Product · Other
Lead sponsor
Red Queen Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Patch as an Analgesic Adjuvant After Surgery

NCT00440830
View directory record Official record
Conditions
Pain
Interventions
nicotine patch, placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1a Study of PMN310 In Healthy Volunteers

NCT06105528
View directory record Official record
Conditions
Healthy Participants
Interventions
PMN310, Placebo
Drug
Lead sponsor
ProMis Neurosciences, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 23, 2026, 6:13 AM EDT
Suspended Phase 2 Interventional

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

NCT00761228
View directory record Official record
Conditions
Brain Injury
Interventions
Apomorphine, Placebo
Drug
Lead sponsor
NeuroHealing Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 23, 2026, 6:13 AM EDT
Suspended Phase 4 Interventional

Semaglutide to Reduce Atrial Fibrillation Burden

NCT05209165
View directory record Official record
Conditions
Atrial Fibrillation, Obesity, Overweight
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067
View directory record Official record
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

NCT02927067
View directory record Official record
Conditions
Cytomegalovirus (CMV)
Interventions
Maribavir, Valganciclovir, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

NCT03905707
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nitrous Oxide Treatment for Tinnitus

NCT03365011
View directory record Official record
Conditions
Tinnitus
Interventions
Nitrous oxide gas for inhalation, Placebo gas for inhalation
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 23, 2026, 6:13 AM EDT
Recruiting Phase 2 Interventional

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

NCT05305911
View directory record Official record
Conditions
Heart Attack, Enlarged Heart
Interventions
SGLT-2 inhibitors, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 23, 2026, 6:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy-Induced Immune Modulation: Part III

NCT03643744
View directory record Official record
Conditions
Actinic Keratosis, Photodynamic Therapy
Interventions
Celecoxib 200mg, Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump

NCT00472134
View directory record Official record
Conditions
Hernia, Ventral
Interventions
bupivacaine, On-Q PainBuster pump
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 6:13 AM EDT
Recruiting Phase 2 Interventional

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

NCT05952934
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Biological · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

NCT01198834
View directory record Official record
Conditions
Ankle Sprains
Interventions
MRX-7EAT, Placebo, Lidocaine, Etodolac
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
33
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Chico, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Not applicable Interventional

Pilot Study of Diet and Behavior in Children With Autism

NCT01625299
View directory record Official record
Conditions
Autism
Interventions
Gluten and dry milk, Placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 23, 2026, 6:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Attentional Bias Modification Training for E-cigarette Users

NCT05112562
View directory record Official record
Conditions
E-cigarette Use, Tobacco Use Cessation
Interventions
Computerized attentional bias modification training, Placebo attention control training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 23, 2026, 6:13 AM EDT
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 23, 2026, 6:13 AM EDT